Buspirone in Rett syndrome respiratory dysfunction

dc.contributor.authorAndaku D.K.
dc.contributor.authorMercadante M.T.
dc.contributor.authorSchwartzman J.S.
dc.date.accessioned2024-03-13T01:43:54Z
dc.date.available2024-03-13T01:43:54Z
dc.date.issued2005
dc.description.abstractThis study details a case of Rett Syndrome where the patient's respiratory dysfunction was improved after buspirone was administered. Polygraphic studies in the waking state, before and after treatment with 5 mg of buspirone twice a day, were obtained. Breathing movements, oxygen saturation and end-tidal carbon were monitored. Average oxygen saturation increased from 86.9 to 91%, and the period of saturation below 90% was reduced by 42.2%. The oxygen saturation improvement observed in this case suggests that buspirone might be useful in treating respiratory dysfunction associated with Rett Syndrome. Controlled clinical trials are needed to provide more evidence.
dc.description.firstpage437
dc.description.issuenumber6
dc.description.lastpage438
dc.description.volume27
dc.identifier.doi10.1016/j.braindev.2004.09.011
dc.identifier.issn0387-7604
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/37867
dc.relation.ispartofBrain and Development
dc.rightsAcesso Restrito
dc.subject.otherlanguageBuspirone
dc.subject.otherlanguageDysfunction
dc.subject.otherlanguageOxygenation
dc.subject.otherlanguageRespiratory
dc.subject.otherlanguageRett syndrome
dc.titleBuspirone in Rett syndrome respiratory dysfunction
dc.typeArtigo
local.scopus.citations38
local.scopus.eid2-s2.0-23944511614
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=23944511614&origin=inward
Arquivos